Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
ALDE 2.81 +0.0% TECK 83.43 +3.4% FVI 11.85 −2.1% SUM 1.32 −0.8% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.240 −5.9% CNC 1.49 +1.4% PHNM 0.340 +4.6% LIO 0.145 −9.4% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.66 +9.9% ALDE 2.81 +0.0% TECK 83.43 +3.4% FVI 11.85 −2.1% SUM 1.32 −0.8% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.240 −5.9% CNC 1.49 +1.4% PHNM 0.340 +4.6% LIO 0.145 −9.4% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.66 +9.9%

Healthcare

Page 138
Earnings

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of

Aug 07, 2025 · 07:00 · QNTM
  1. Aug 07, 2025 · 07:00 · DR

    Medical Facilities Corporation Announces Second Quarter Results and New $40 Million Credit Agreement

    Medical Facilities Corporation Announces Second Quarter Results and New $40 Million Credit Agreement

    01
  2. Aug 06, 2025 · 19:20 · MBIO

    Mindbio awaits phase 2B trial results for MB22001

    Mindbio awaits phase 2B trial results for MB22001

    02
  3. Aug 06, 2025 · 17:52 · EXE

    Extendicare Announces 2025 Second Quarter Results

    Extendicare Announces 2025 Second Quarter Results

    03
  4. Aug 06, 2025 · 17:43 · CRDL

    Cardiol posts results from Archer myocarditis trial

    Cardiol posts results from Archer myocarditis trial

    04
  5. Aug 06, 2025 · 17:16 · APLI

    Appili releases tularemia vaccine results

    Appili releases tularemia vaccine results

    05
  6. Aug 06, 2025 · 16:30 · APS

    Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

    Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

    06
  7. Aug 06, 2025 · 08:00 · CTX

    Crescita Reports Second Quarter 2025 Results

    Crescita Reports Second Quarter 2025 Results

    07
  8. Aug 05, 2025 · 20:00 · OTC

    Ocumetics begins patient recruitment for FIH lens study

    Ocumetics begins patient recruitment for FIH lens study

    08
  9. Aug 05, 2025 · 19:46 · BUX

    Biomark expands Quebec lab, doubles testing capacity

    Biomark expands Quebec lab, doubles testing capacity

    09
  10. Aug 05, 2025 · 19:30 · AIAI

    Netramark signs NetraAI contract with Asklepion

    Netramark signs NetraAI contract with Asklepion

    10
  11. Aug 05, 2025 · 18:02 · QNTM

    Quantum Biopharma receives Lucid-MS study report

    Quantum Biopharma receives Lucid-MS study report

    11
  12. Aug 05, 2025 · 17:57 · GUD

    Knight submits Crexont Parkinson's drug in Mexico

    Knight submits Crexont Parkinson's drug in Mexico

    12
  13. Aug 05, 2025 · 17:30 · MDP

    Medexus's Grafapex add-on payment okayed by Medicare

    Medexus's Grafapex add-on payment okayed by Medicare

    13
  14. Aug 05, 2025 · 09:24 · BNXT

    Bionxt's European patent applications accepted

    Bionxt's European patent applications accepted

    14
← Newer Older →